The Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with a consortium of research and technological institutions to develop a novel vaccine to provide protection against COVID-19 caused by current and future SARS-CoV‑2 variants, as well as to protect against other SARS-like Betacoronaviruses*. The project will be led in manufacturing efforts by CPI to advance the novel vaccine developed at Caltech and The University of Oxford, and manufactured using microbes engineered by industrial biotechnology leader, Ingenza Ltd. Source: CPI Press release 5/7/2022